

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10599578
Filing Date	2005-03-30
First Named Inventor	Malcolm King
Art Unit	1616
Examiner Name	Andriae M. Holt
Attorney Docket Number	14628-2

U.S.PATENTS						Remove		
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Patent citation information please click the Add button.						Add		
U.S.PATENT APPLICATION PUBLICATIONS						Remove		
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1							
If you wish to add additional U.S. Published Application citation information please click the Add button.						Add		
FOREIGN PATENT DOCUMENTS						Remove		
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>
If you wish to add additional Foreign Patent Document citation information please click the Add button						Add		
NON-PATENT LITERATURE DOCUMENTS						Remove		
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T ⁵	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10599578
		Filing Date	2005-03-30
		First Named Inventor	Malcolm King
		Art Unit	1616
		Examiner Name	Andriae M. Holt
		Attorney Docket Number	14628-2

	1	KING, M. et al., "Mucomodulator therapy in cystic fibrosis: balancing mucus clearability against the spread of airborne pathogens", Pediatr. Pulmonol., 2004, Vol. 37, pages 77-79.	<input type="checkbox"/>
	2	ZAHM, J.M. et al., "The role of mucus sol phase in clearance by simulated cough", Biorheology, 1989, Vol. 26, pages 747-752.	<input type="checkbox"/>
	3	RAYNAL, B.D.E. et al., "Calcium-dependent protein interactions in MUC5B provide reversible cross-links in salivary mucus", J. Biol. Chem., 2003, Vol. 278, No. 31, pages 28703-28710.	<input type="checkbox"/>
	4	KWANG, H.K. et al., "Inhibition of mucin release from airway goblet cells by polycationic peptides", Am. J. Physiol-lung, 1999, Vol 277, pages 811-815.	<input type="checkbox"/>
	5	LINDEMANN, R.A., "Bacterial activation of human natural killer cells: role of cell surface lipopolysaccharide", Infect. Immun., 1988, Vol. 56, No. 5, pages 1301-1308.	<input type="checkbox"/>
	6	ZAYAS, G. et al., "A new paradigm in respiratory hygiene: increasing the cohesivity of airway secretions to improve cough interaction and reduce aerosol dispersion", BMC Pulmonary Medicine, 2005, Vol. 5, No. 11, pp. 1-12.	<input type="checkbox"/>
	7	KING, M., "Mucus and its role in airway clearance and cytoprotection", Airways and Lung Defence, Ch. 35, pp. 409-416.	<input type="checkbox"/>
	8	ZAYAS, G. et al., "A new paradigm in respiratory hygiene: modulating respiratory secretions to contain cough bioaerosol without affecting mucus clearance", BMC Pulmonary Medicine 2007, 7:11, 1-13.	<input type="checkbox"/>
	9	RUBIN, Bruce K., "The Pharmacologic Approach to Airway Clearance: Mucoactive Agents", Wake Forest University School of Medicine, Paediatr. Respir. Rev., 2006.	<input type="checkbox"/>
	10	SHIBUYA, Yasuhiro, et al., "Effect of osmolality on Mucociliary Transportability and Rheology of Cystic Fibrosis and Bronchiectasis Sputum", Respirology 2003, 8, pp. 181-185.	<input type="checkbox"/>
	11	FULORIA, M., et al., "Evaluating the Efficacy of Mucoactive Aerosol Therapy", Respir. Care 2000; Vol. 45, No. 7, pp. 868-873	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number	10599578
		Filing Date	2005-03-30
		First Named Inventor	Malcolm King
		Art Unit	1616
		Examiner Name	Andriae M. Holt
		Attorney Docket Number	14628-2

	12	KING, M. et al., "Clearance of mucus by simulated cough", J Appl Physiol 1985; 58: 1776-1782.	<input type="checkbox"/>
	13	JEANNERET-GROSJEAN et al., "Sampling techniques and rheology of human bronchial mucus", Am Rev Respir Dis 1988; 137: 707-710.	<input type="checkbox"/>
	14	RUBIN, BK et al., "Mucus-depleted frog palate as a model for the study of mucociliary clearance", J Appl Physiol 1990; 69: 424-429.	<input type="checkbox"/>
	15	TOMKIEWICZ, RP et al., "Amiloride inhalation therapy in cystic fibrosis: Influence on ion content, hydration and rheology of sputum", Am Rev Respir Dis 1993; 148: 1002-1007.	<input type="checkbox"/>
	16	HARDY, JG et al., "Lung deposition of a Nacystelyn metered dose inhaler formulation", J Aerosol Med 1993; 6:37-34.	<input type="checkbox"/>
	17	KING, M et al., "Relationship with clearance funtions", Chapter 7 of: Takishima T, Shimura S, eds. Airway Secretion: Phusiological Bases for the Control of Mucus Hypersecretion (Lung Biology in Health and Disease Series) New York: Marcel Dekker, 1994, 283-314.	<input type="checkbox"/>
	18	FENG, W et al., "Improved clearability of cystic fibrosis sputum with dextran treatment in vitro", Am J Respir Crit Care Med 1998; 157: 710-714.	<input type="checkbox"/>
	19	KING, M et al., "The Evolution of the frog palate model from mucociliary clearance", In: Baum G. ed. Cilia, Mucus and Mucociliary Interactions. New York: Marcel Dekker, 1998, 191-201.	<input type="checkbox"/>
	20	FINLAY, WH et al., "Lung delivery of aerosolized dextran" Am J Respir Crit Care Med 2000; 161:91-97.	<input type="checkbox"/>
	21	VANDERBIST, F et al., "Deposition of nacystelyn from a dry powder inhaler in healthy volunteers and cystic fibrosis patients", Drug Dev Ind Pharm 2001; 27:205-12.	<input type="checkbox"/>
	22	KING, M et al., "Pharmacological apporaches to discovery and development of new mucolytic agents", Advanced Drug Delivery Review 2002;54:1475-1490.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10599578
	Filing Date	2005-03-30
	First Named Inventor	Malcolm King
	Art Unit	1616
	Examiner Name	Andriae M. Holt
	Attorney Docket Number	14628-2

	23	KING, M., "Mucus, mucociliary clearance and coughing", In:Bates DV. Respiratory Function in Disease, 3rd ed. Philadelphia: Saunders, 1989: 69-78.	<input type="checkbox"/>
	24	KING, M., "Role of Mucus viscoelasticity in cough clearance", Biorheology 1987; 24:589-597.	<input type="checkbox"/>
	25	ZAYAS, JG et al., "Tracheal mucus rheology in patients undergoing diagnostics bronchoscopy: Interrelations with smoking and cancer", Am Rev Respir Dis 1990; 141: 1107-1113.	<input type="checkbox"/>
	26	WANNER, A et al., "Mucocillary clearance in the airways", Am J Respir Crit Care Med 1996; 154: 1868-1902.	<input type="checkbox"/>
	27	KING, M et al., "Mucus physiology and pathophysiology: Therapeutic aspects", Chapter 13 of: Derenne JP, Whitelaw WA Similowski T, eds. Acute Respiratory Failure in COPD (Lung Biology in Health and Disease Series). New York: Marcel Dekker, 1996: 391-411.	<input type="checkbox"/>
	28	KING, M et al., "Mucus controlling agents: Past and present", IN:RAu JL, ed. Aerosolized Drugs for the Respiratory Tract. Respir Care Clinics N Amer 1999: 575-594.	<input type="checkbox"/>
	29	KING, M et al., "Pharmacological approaches to discovery and development of new mucolytic agents", Advanced Drug Delivery Reviews 2002; 54: 1475-1490.	<input type="checkbox"/>
	30	KING, M., "Magnetic Microrheometer", In: Baraga PC, Allegra L, eds. Methods in Bronchial Mucology. New York: Raven Press, 1988, 73-83.	<input type="checkbox"/>
	31	OHTAKE, K et al., "Analysis of transient and reversible effects of poly-L-arginine on the in vivo nasal absorption of FITC-dextran in rats", Journal of Controlled Release 82, 2002, 263-275.	<input type="checkbox"/>
	32	MARRIOTT, C et al., "Changes in the Gel Properties of Tracheal Mucus Induced by Divalent Cations", Biorheology Vol. 16, pp. 331-337, 1979.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number	10599578
	Filing Date	2005-03-30
	First Named Inventor	Malcolm King
	Art Unit	1616
	Examiner Name	Andriae M. Holt
	Attorney Docket Number	14628-2

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.